Emergent Biosolutions’ (EBS) “Buy” Rating Reaffirmed at Chardan Capital

Chardan Capital restated their buy rating on shares of Emergent Biosolutions (NYSE:EBS) in a report issued on Thursday, AnalystRatings.com reports. The brokerage currently has a $71.00 target price on the biopharmaceutical company’s stock.

A number of other analysts also recently issued reports on EBS. Wells Fargo & Co raised shares of Emergent Biosolutions from a market perform rating to an outperform rating and increased their price target for the stock from $61.00 to $64.00 in a report on Wednesday, September 4th. ValuEngine raised shares of Emergent Biosolutions from a hold rating to a buy rating in a report on Wednesday, September 4th. Laidlaw set a $72.00 price objective on shares of Emergent Biosolutions and gave the company a buy rating in a report on Wednesday, September 4th. Cowen reaffirmed a hold rating and set a $67.00 price objective on shares of Emergent Biosolutions in a report on Thursday. Finally, Guggenheim initiated coverage on shares of Emergent Biosolutions in a report on Thursday, September 12th. They set a buy rating and a $65.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $69.00.

NYSE EBS traded down $0.96 during mid-day trading on Thursday, reaching $54.04. 350,011 shares of the stock were exchanged, compared to its average volume of 451,394. The business’s 50 day moving average is $54.01 and its 200-day moving average is $48.08. Emergent Biosolutions has a 1 year low of $39.11 and a 1 year high of $73.89. The company has a market capitalization of $3.00 billion, a P/E ratio of 23.19, a P/E/G ratio of 0.96 and a beta of 1.55. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.53 and a current ratio of 2.30.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $1.21 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.58. Emergent Biosolutions had a negative net margin of 2.04% and a positive return on equity of 6.68%. The firm had revenue of $311.80 million for the quarter, compared to the consensus estimate of $289.16 million. During the same period in the prior year, the firm posted $0.55 earnings per share. The firm’s quarterly revenue was up 79.6% compared to the same quarter last year. Equities analysts predict that Emergent Biosolutions will post 3.04 earnings per share for the current fiscal year.

In other Emergent Biosolutions news, Director Kathryn C. Zoon sold 1,509 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $56.12, for a total transaction of $84,685.08. Following the transaction, the director now directly owns 21,494 shares of the company’s stock, valued at $1,206,243.28. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 14.10% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. Usca Ria LLC acquired a new stake in shares of Emergent Biosolutions in the third quarter valued at about $35,000. Quadrant Capital Group LLC raised its position in shares of Emergent Biosolutions by 1,510.2% in the third quarter. Quadrant Capital Group LLC now owns 789 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 740 shares during the last quarter. Rehmann Capital Advisory Group raised its position in shares of Emergent Biosolutions by 303.9% in the second quarter. Rehmann Capital Advisory Group now owns 1,034 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 778 shares during the last quarter. Clarus Wealth Advisors raised its position in shares of Emergent Biosolutions by 30.7% in the second quarter. Clarus Wealth Advisors now owns 2,114 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 496 shares during the last quarter. Finally, Private Capital Group LLC raised its position in shares of Emergent Biosolutions by 11.1% in the second quarter. Private Capital Group LLC now owns 2,397 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 239 shares during the last quarter. 87.75% of the stock is currently owned by institutional investors and hedge funds.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

Featured Article: Google Finance Portfolio Workaround

Analyst Recommendations for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.